We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT) (COMBAAT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04705844
Recruitment Status : Withdrawn (study withdrawn prior to screening subjects)
First Posted : January 12, 2021
Last Update Posted : March 3, 2022
Pharm-Olam, LLC
Chemical, Biological, Radiological, and Nuclear Medical
Information provided by (Responsible Party):
Ology Bioservices

No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : September 2022
Estimated Study Completion Date : September 2022